Using patented purification methods and a community-first growth strategy, the Root Brands is redefining what it means to ...

The company recently shook up its leadership structure as it pursues a Phase 2 study.

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from ...

The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

Unexpected delays, infighting and a staffing crisis are fueling investors’ unease.

China's Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) said Thursday night it would license an experimental cancer ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s ...

Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On December 9, 2025, Moleculin Biotech announced an update on its pivotal Phase 2B/3 ...